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Abstract: Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. 
In comparative trials, across dose ranges this statin reduced low-density lipoprotein (LDL) 
cholesterol and total cholesterol significantly more than atorvastatin, simvastatin, and pravastatin, 
and triglycerides significantly more than simvastatin and pravastatin. In healthy subjects with 
normal LDL cholesterol and elevated C-reactive protein, rosuvastatin treatment significantly 
decreased the incidence of cardiovascular events. Its chemical and pharmacokinetic properties 
(with a low lipophilicity and poor capacity to inhibit cytochrome P450 enzymes) suggest a 
very limited penetration in extrahepatic tissues with a lower risk of muscle toxicity and unlike 
metabolically mediated drug–drug interactions. This article reviews the most recent data on 
the pharmacologic and clinical properties of rosuvastatin, in order to enable the correct use of 
this statin for the treatment of hypercholesterolemia.
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Introduction
In July 2004, an update of treatment guidelines for hypercholesterolemia was published 
by the National Cholesterol Education Program Adult Treatment Panel (NCEP-
ATP III).1 This document reviews the results of the most recent clinical trials and 
assessed their implications for cholesterol management. Therapeutic lifestyle changes 
were emphasized as an essential modality in clinical management of dyslipidemia, 
and the benefit of cholesterol-lowering therapy was confirmed in high-risk patients. 
The ATP III low-density lipoprotein (LDL) cholesterol treatment goals and endpoints 
for theraputic lifestyle changes and drug therapy in different risk categories are sum-
marized in Table 1.
LDL cholesterol is the primary target of cholesterol-lowering therapy with 
agents such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (commonly referred to as statins). Currently six statins are approved and 
marketed in the United States and European countries. The clinical use of these 
drugs for primary or secondary prevention in patients with hypocholesterolemia 
has significantly reduced morbidity and mortality associated with coronary 
heart disease (CHD).2–7 Unfortunately, a number of these agents can reduce 
LDL cholesterol levels by only 30% to 35%, which may not bring many subjects 
to their NCEP-ATP III goals.8
Moreover, the higher-potency agents (simvastatin, lovastatin, atorvastatin) have 
extensive extrahepatic tissue penetration and show potential drug interactions that Drug, Healthcare and Patient Safety 2009:1 26
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may have remarkable safety implications.9 Rosuvastatin, 
the most recently approved HMG-CoA reductase inhibitor, 
has demonstrated a potent lipid-lowering effect associated 
with a good tolerability profile and a lower risk of pharma-
cokinetic interactions. This statin is a hydrophilic compound 
with poor penetration in extrahepatic tissue, and it does not 
seem to exhibit significant cytochrome (CYP) P450 drug 
interactions, as do several of the other HMG-CoA reductase 
inhibitors.10
This reviews the pharmacologic and pharmacokinetic 
properties of rosuvastatin, comparing its efficacy and safety 
with other that of currently available HMG-CoA reductase 
inhibitors.
Pharmacology
Statins are natural, fungus resultant, mevinic acid derived 
(simvastatin, lovastatin, pravastatin), or synthetic, heptenoic 
acid derived (atorvastatin, cerivastatin, fluvastatin).11
Rosuvastatin is a synthetic HMG-CoA reductase inhibi-
tor belonging to a new novel series of methanesulfonamide 
pyrimidine and N-methanesulfonyl pyrrole-substituted 
3,5-dihydroxy-6-heptenoates (heptenoic acid-derivative 
combined with a pyrimidine and sulfonamide group). The 
enzyme inhibition is reversible, competitive with the sub-
strate HMG-CoA and noncompetitive with the cosubstrate 
nicotinamide-adenine dinucleotide phosphate (NADPH). Its 
low lipophilicity is conferred by the addition of a stable polar 
methane sulfonamide group as a hydrophilic moiety besides 
the characteristic statin pharmacophore.10–12
The LDL cholesterol-lowering effect of statins is derived 
from their inhibitory action on HMG-CoA reductase in the 
hepatocytes. These compounds directly bind in a tight and 
reversible manner to a specific binding site on the HMG-CoA 
reductase enzyme. Moreover, rosuvastatin and atorvastatin 
were found to have additional bonding interactions at the 
enzyme complex as compared to other statins. The addition 
of a methane sulfonamide group to the rosuvastatin molecule, 
even though it increases hydrophilicity, results in enhanced 
interaction with the HMG-CoA enzyme and leads to a more 
potent enzyme inhibition, owing to the appearance of ionic 
binding interactions.10–13
Rosuvastatin shows a very high affinity for the active 
site of the HMG-CoA reductase, four times greater than 
the affinity of the natural substrate HMG-CoA for the 
enzyme. The high affinity and tight binding of rosuvastatin 
to HMG-CoA reductase leads to a slow recovery of enzyme 
activity after removal of free inhibitor. In fact, hepatic 
cholesterol synthesis in rats was found to be inhibited by 
62% at 7 hours after oral dosing compared to −7% and 13% 
for atorvastatin and simvastatin, respectively.13,14 The binding 
properties of this statin for the target enzyme are reflected in 
the drug concentration needed to block 50% of sterol synthe-
sis in the rat hepatocyte (IC50). The mean IC50 of rosuvastatin 
in primary rat hepatocytes (0.16 nM on log scale) is signifi-
cantly lower than the mean IC50 of other statins (1.16 for 
atorvastatin, 2.74 for simvastatin, 3.78 for fluvastatin, and 
6.93 for pravastatin). Therefore rosuvastatin was found to 
be a significantly more potent inhibitor of hepatocyte sterol 
synthesis than any of the statins currently available.14,15
Moreover, rosuvastatin is significantly less lipophilic than 
other HMG-CoA reductase inhibitors except pravastatin.16 
Hepatocyte concentrations of drug are not influenced by the 
statin lipophilicity because active uptake occurs, but differ-
ences in lipophilicity of statins are related to their penetration 
Table 1 ATP iii LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and lipid-lowering therapy in different risk 
categories1
Risk category LDL-C goal Initiate TLC Consider drug therapy
High risk: CHD or CHD equivalentsa  
(10-year risk 20%)
100 mg/dL 
(optional goal: 
70 mg/dL)
100 mg/dL 100 mg/dL
Moderately high risk: 2 risk factorsb  
(10-year risk 10% to 20%)
130 mg/dL 130 mg/dL 130 mg/dL
Moderate risk: 2 risk factorsb  
(10-year risk 10%)
130 mg/dL 130 mg/dL 160 mg/dL
Low risk: 0–1 risk factor2 160 mg/dL 160 mg/dL 190 mg/dL
aCHD includes history of myocardial infarction, unstable angina, stable angina, coronary artery procedures, or evidence of clinically significant myocardial ischemia; CHD equivalents 
include clinical manifestations of noncoronary forms of atherosclerotic disease, diabetes, and 2 or more risk factors with 10-year risk for hard CHD  20%.
brisk factors include: cigarette smoking, hypertension (blood pressure 140/90 mm Hg or on antihypertensive medication), low high-density lipoprotein (HDL) cholesterol 
(40 mg/dL), family history of premature CHD, and age (men  45 years, women  55 years).
Abbreviations: LDL-C, low-density lipoprotein cholesterol; TLC, therapeutic lifestyle changes; CHD, coronary heart disease.Drug, Healthcare and Patient Safety 2009:1 27
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into extrahepatic tissues. Lipophilicity and penetration in 
nonhepatic tissues have potential clinical implications for 
muscle toxicity. Cerivastatin, the most lipophilic agent of this 
class, shows a very great penetration in extrahepatic tissues, is 
the most potent inhibitor of vascular smooth muscle prolifera-
tion, and had the largest number of cases of rhabdomyolysis. 
On the contrary, pravastatin, the most hydrophilic statin, has 
a rhabdomyolysis rate which is approximately one-third that 
of lovastatin and does not show a dose-related increase in the 
risk of muscle toxicity as with lovastatin.10,16,17
Pharmacokinetics and drug–drug 
interactions
The oral bioavailability of rosuvastatin is approximately 20%, 
or rather lower than cerivastatin (which has a bioavailability 
of 60%), but higher than lovastatin and simvastatin, and 
comparable to that of pravastatin, fluvastatin, and atorvastatin. 
Food is known to reduce rosuvastatin’s rate of absorption by 
20%, but the extent of absorption is unchanged.
The peak plasma concentration (Cmax) of 6.1 ng/mL 
is reached at 5 hours after a single oral dose of 20 mg. 
Prolonged dosing with 20 mg once daily leads to a 
steady state Cmax of 9.7 ng/mL, which occurs 3 hours 
after dosing. In pharmacokinetic trials, the Cmax and the area 
under the concentration time curve (AUC0–24) demonstrated 
an approximately linear relation throughout the dosage 
range of 5 to 80 mg after single and seven daily doses. 
Steady state tmax ranged from 3 to 5 hours, and it was longer 
than other currently available statins (with tmax values usually 
lower than 3 hours).10,18
At steady state, the mean volume of distribution for 
rosuvastatin is about 130 L, and it is tightly bound in a 
reversible manner to plasma proteins (88%), while other 
statins are more than 95% protein bound except pravastatin 
(which is approximately 50% bound).11
Metabolism of rosuvastatin and its interactions with 
cytochrome P450 isoenzymes were evaluated in vitro 
using human hepatic microsomes. No significant inhibi-
tory effect was noted on CYP1 A2, 2C9, 2C19, 2D6, 2E1, 
and 3 A4 activity. The most potent inhibition was found 
against the CYP2C9, but the enzyme activity was reduced 
by only 10%.19 The metabolism of rosuvastatin via cultured 
human hepatocytes (3% to 50% over 3 days) produces 
an N-desmethyl-metabolite and a 5S-lactone product. 
The N-desmethyl-metabolite is 7-fold less potent than 
rosuvastatin for inhibition of HMG-CoA reductase activity.10 
The slow metabolism and the limited inhibitory effect of 
rosuvastatin on CYP isoenzymes suggest that it is unlikely 
to cause any significant pharmacokinetic interactions with 
other drugs metabolized by hepatic CYP isoenzymes. On 
the contrary, lovastatin, simvastatin, and atorvastatin are 
extensively metabolized by CYP3 A4, and inhibitors of 
this enzymatic system (such as itraconazole) were found to 
increase serum concentrations of these statins by several-fold, 
with an increased risk of muscle toxicity.19,20
Recovery of rosuvastatin is primarily via the fecal route 
of elimination: approximately 70% of absorbed dose is 
eliminated via bile secretion, and 30% via renal excretion. 
The circulating plasma half-life of rosuvastatin is about 
20 hours.10,16
Statins are effective inhibitors of P-glycoprotein, which 
is cell membrane-associated and transports many drug sub-
strates across the intestinal wall. Inhibition of P-glycoprotein 
may influence the pharmacokinetic and pharmacodynamic 
properties of drugs that are substrates of this transporter, 
and may lead to other important drug–drug interactions. 
Lovastatin, simvastatin, and atorvastatin are very potent 
inhibitors of P-glycoprotein in higher concentrations, and 
show important drug–drug interactions with digoxin, which 
is transported by P-glycoprotein.21,22 To date there are no data 
available assessing whether rosuvastatin is an inhibitor or a 
substrate for P-glycoprotein.
Itraconazole is a potent inhibitor of CYP3 A4 and 
P-glycoprotein, and is known to interact with other statins. In 
two randomized, double-blind, placebo-controlled trials the 
effect of itraconazole on the pharmacokinetics of rosuvastatin 
was evaluated in 26 healthy volunteers. In these studies, 
the coadministration of itraconazole produced only modest 
increases in plasma concentrations of rosuvastatin, which 
are unlikely to be of clinical relevance.23
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Lipid-lowering therapy is frequently requested for 
the treatment of hypocholesterolemia associated with 
antiretroviral drugs in patients with human immunodeficiency 
virus (HIV) infection. Particularly, protease inhibitors 
(PI) are extensively metabolized by hepatic CYP 3A4 
and concomitant use of statins could lead to significant 
drug–drug interactions with increased risk of drug toxicity. 
Because pharmacokinetic studies have demonstrated that 
the rosuvastatin metabolism is not dependent on CYP 3A4 
isoenzyme, its use could be considered in PI-treated subjects 
owing to the low risk of pharmacological interactions.
In an open-label, randomized, prospective study we have 
evaluated over at least 12 months the efficacy and safety 
of rosuvastatin, pravastatin, and atorvastatin in 94 HIV-
infected subjects on a stable PI-based antiretroviral therapy 
and presenting hypocholesterolemia. During the 12-month 
follow-up all administered statins showed a favorable toler-
ability profile, and patients’ plasma HIV viral load did not 
present any significant variation. Particularly, no significant 
increases in serum levels of creatine phosphokinase (CPK) 
or liver function tests were reported.24
However, two recent studies showed potential pharmaco-
kinetic interactions between rosuvastatin and PIs.
A prospective study assessed drug–drug interactions of 
rosuvastatin with atazanavir/ritonavir and fosamprenavir/
ritonavir in 6 HIV-negative healthy adult volunteers. Com-
pared to baseline, AUC0–24 and Cmax of rosuvastatin increased 
by 213% and 600%, respectively, when given with atazanavir/
ritonavir, while coadministration with fosamprenavir/ritonavir 
did not significantly affect plasma concentrations of the 
statin. Therefore, atazanavir/ritonavir significantly increases 
the plasma levels of rosuvastatin, most likely by increasing 
its oral bioavailability, but the clinical significance of this 
pharmacokinetic interaction is unknown.25
An open-label, prospective study evaluated drug-drug 
interaction between rosuvastatin and lopinavir/ritonavir 
in 15 HIV-negative healthy adult volunteers. Rosuvastatin 
AUC0–24 and Cmax were unexpectedly increased 2.1- and 
4.7-fold, respectively, when given in combination with the 
PI, and there was 1 asymptomatic elevation in serum levels 
of CPK and liver function tests. Therefore, rosuvastatin and 
lopinavir/ritonavir should be used with caution until the 
safety and appropriate dosing of this combination have been 
demonstrated in larger populations.26
Laboratory and clinical efficacy
Rosuvastatin was found to be highly efficacious in reducing 
plasma LDL cholesterol levels and favorably modifying the 
other lipid and apolipoprotein parameters in patients with 
hypercholesterolemia in both short-term and long-term 
clinical trials. Moreover, in pairwise comparisons, rosuvas-
tatin showed a significantly higher efficacy in reducing LDL 
cholesterol than milligram-equivalent doses of other statins 
currently available.
Dosing of rosuvastatin ranging from 1 to 80 mg daily 
over 6 weeks has resulted in LDL-cholesterol reductions 
compared with the baseline values from 34% to 65%, and 
the LDL cholesterol reduction at the probable starting dose 
range (5 to 10 mg) was 43% to 51%.27
In a direct comparative trial, rosuvastatin or atorvastatin 
was administered to patients with familial heterozygous 
hypercholesterolemia. Subjects were randomized to 
either 20 mg of rosuvastatin or atorvastatin and the dose 
was doubled at 6-week periods until all patients reached 
the maximum dose of 80 mg for both drugs at weeks 
12 to 18. Decreases in LDL cholesterol concentrations 
were significantly greater for rosuvastatin compared 
with atorvastatin at all time points, and 61% of patients 
taking rosuvastatin reached target goals according to 
NCEP-ATP II guidelines, compared to 46% of those taking 
atorvastatin.28
The STELLAR study29 was a 6-week, open-label, 
randomized, multicenter trial comparing rosuvastatin 
with atorvastatin, pravastatin, and simvastatin across 
dose ranges for reduction of LDL cholesterol, changes in 
other lipid parameters, and achievement of NCEP-ATP III 
LDL-cholesterol goals.
After a 6-week dietary lead-in period, 2431 adult subjects 
with hypercholesterolemia were randomized to therapy with 
rosuvastatin (10, 20, 40, or 80 mg daily), atorvastatin (10, 
20, 40, or 80 mg daily), simvastatin (10, 20, 40, or 80 mg 
daily), or pravastatin (10, 20, or 40 mg daily). At the end 
of 6-weeks follow-up, across-dose analyses showed that 
rosuvastatin 10 to 80 mg reduced LDL cholesterol by a mean 
of 8.2% more than atorvastatin 10 to 80 mg, 26% more than 
pravastatin 10 to 40 mg, and 12%–18% more than simvastatin 
10 to 80 mg (all P  0.001). Mean percent changes in high-
density lipoprotein (HDL) cholesterol levels were +7.7% 
to +9.6% compared with +2.1% to +6.8% in all other groups. 
Moreover, rosuvastatin reduced total cholesterol significantly 
more than all comparators, and triglycerides significantly 
more than simvastatin and pravastatin. The NCEP-ATP III 
LDL cholesterol goals were achieved by 82% to 89% of 
subjects treated with rosuvastatin 10 to 40 mg compared with 
69% to 85% of patients treated with atorvastatin 10 to 80 mg, 
and drug tolerability was comparable across treatments.29 Drug, Healthcare and Patient Safety 2009:1 29
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Effects of statins at different dosages in lowering LDL 
cholesterol levels are summarized in Table 2.
A substudy of the STELLAR trial assessed non-
HDL cholesterol, apolipoprotein (apo) B, and lipid and 
apolipoprotein ratios that included both atherogenic and 
antiatherogenic lipid components in 2,268 patients with 
hypercholesterolemia. All participants were randomized 
to therapy with rosuvastatin (10, 20, 40, or 80 mg daily), 
atorvastatin (10, 20, 40, or 80 mg daily), simvastatin (10, 20, 
40, or 80 mg daily), or pravastatin (10, 20, or 40 mg daily) 
for 6 weeks. At the end of follow-up, rosuvastatin reduced 
non-HDL cholesterol, apo B, and all lipid and apolipoprotein 
ratios assessed significantly more than milligram-equivalent 
doses of atorvastatin, and milligram-equivalent or higher 
doses of simvastatin and pravastatin (all P  0.002).30
A post-hoc subanalysis of the STELLAR trial evaluated 
the effects of maximal doses of rosuvastatin and atorvastatin 
on LDL cholesterol and small dense LDL (sLDL) choles-
terol levels in 271 hyperlipidemic patients. All participants 
were randomized to therapy with rosuvastatin 40 mg daily 
or atorvastatin 80 mg daily for 6 weeks. Rosuvastatin was 
significantly more effective than atorvastatin in reducing 
LDL cholesterol, sLDL cholesterol, total cholesterol/HDL 
cholesterol ratio, and non-HDL cholesterol, even though the 
magnitude of these differences was modest, and both statins 
caused similar decreases in triglyceride levels.31
Two studies have evaluated the efficacy of rosuvastatin 
therapy after a 52-week follow-up. In the first randomized, 
double-blinded, multicenter study, 412 subjects with 
elevated LDL cholesterol levels received fixed doses of 
rosuvastatin (5 or 10 mg daily) or atorvastatin (10 mg 
daily) for 12 weeks, followed by dose adjustements up 
to 80 mg if the NCEP-ATP III goals were not met. Both 
doses of rosuvastatin resulted in greater LDL cholesterol 
reductions than atorvastatin at 12 weeks (46% and 50%, 
respectively, versus 39%; P  0.001 for both groups) and 
52 weeks (47% and 53%, respectively, versus 44%; P  0.05 
and P  0.001).32
In a similarly designed trial, 477 patients with 
hypocholesterolemia received fixed doses of rosuvastatin (5 or 
10 mg daily), pravastatin (20 mg), or simvastatin (20 mg) for 
12 weeks followed by 40 weeks of liberal-dose titration 
up to 80 mg for rosuvastatin and simvastatin and 40 mg 
for pravastatin. After 52 weeks, more rosuvastatin-treated 
subjects achieved the NCEP-ATP III LDL cholesterol goals 
(88% and 87.5%, respectively) than recipients of pravastatin 
(60%) or simvastatin (73%).33
In recent years, some evidence has suggested that the 
“quality” rather than the “quantity” of LDL produces a 
direct influence on cardiovascular risk. There are at least four 
major subspecies of LDL particles, and the predominance 
of sLDL has been associated with a significantly higher risk 
of coronary artery disease.34 To date, only few studies have 
directly investigated if rosuvastatin may alter LDL size and 
subclasses, but this statin seems modulate significantly LDL 
size and subclasses towards less atherogenic particles as well 
as the LDL particle number, as indirectly measured by the 
levels of apo B.35
The JUPITER trial36 was a randomized, double-blind, 
placebo-controlled study designed to compare whether rosu-
vastatin (20 mg daily) versus placebo would reduce major 
cardiovascular events in 17,802 apparently healthy patients 
with low to normal LDL cholesterol levels but elevated 
C-reactive protein (CRP) levels. Notably, this trial was pre-
maturely interrupted after a median follow-up of 1.9 years 
based on unequivocal evidence of a reduction in cardiovas-
cular morbidity and mortality in rosuvastatin-treated patients. 
The rates of first major cardiovascular events (defined as non-
fatal myocardial infarction, nonfatal stroke, hospitalization 
for unstable angina, arterial revascularization procedure, or 
confirmed death from cardiovascular causes) were 0.77 and 
1.36 per 100 person-years of follow-up in the rosuvastatin 
and placebo groups, respectively (P  0.00001).36
In an analysis of 15,548 subjects participating in the 
JUPITER trial (87% of full cohort), patients allocated to rosu-
vastatin who achieved LDL cholesterol less than 1.8 mmol/L 
had a 55% reduction in rate of vascular events, and those 
achieving CRP less than 2 mg/L a 62% reduction. Particu-
larly, in rosuvastatin-treated patients achieving both LDL 
cholesterol less than 1.8 mmol/L and CRP less than 2 mg/L, 
a 65% reduction in vascular events was recorded.37
Safety
The HMG-CoA reductase inhibitors are overall very safe, 
especially in light of the ability of this drug class to reduce 
morbidity and mortality. However, the withdrawal of 
Table 2 Efficacy of statins at different daily doses in reducing LDL 
cholesterol concentrations versus respective baseline values after 
a 6-week therapy1,29
Daily doses 10 mg 20 mg 40 mg 80 mg
Pravastatin −20% −24% −34% –
Simvastatin −28% −35% −41% −46%
Atorvastatin −38% −43% −48% −51%
rosuvastatin −45% −52% −55% –Drug, Healthcare and Patient Safety 2009:1 30
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cerivastatin because of excess cases of fatal rhabdomyolysis 
has raised awareness of this otherwise very rare complication 
of treatment, and there is an appropriately enhanced concern 
about adverse effects associated with these drugs.
From 1997 to 2000 there were 387 cases of rhabdomyolysis 
associated with cerivastatin therapy, which represented about 
50% of all of the cases spontaneously reported in association 
with statin therapy over this period. In comparison, 
simvastatin was responsible for 24% of the total, atorvastatin 
for 11%, and pravastatin for 9%. In a recent report using US 
data, there were 0.15 cases of death from rhabdomyolysis per 
million prescriptions for all statins, but 3.16 cases per million 
prescriptions for cerivastatin alone. The relative high number 
of cases of rhabdomyolysis for cerivastatin may be related 
to its greater lipophilicity and penetration in extrahepatic 
tissues, as described previously.38,39 However, a population-
based cohort study found that the use of statins in general 
was associated with a greater risk of myopathy than nonuse, 
but the absolute risk of myopathy was minimal.40
A review of rosuvastatin’s pooled safety data demonstrated 
that incidence of adverse events was comparable to those 
of the other statins. The most frequently reported adverse 
events (incidence 5%) during rosuvastatin therapy in the 
controlled phase II/III trials included pharyngitis (12.2%), 
pain (6.7%), headache (6.6%), flu syndrome (5.3%), and 
myalgia (5.1%). The frequency of elevation in alanine 
amino-transferase (ALT) was 0.5%, and the incidence of 
myopathy (CPK levels  10 times upper limit of normal 
(ULN) with muscle symptoms including weakness, aching, 
or tenderness) was 0.2%. All cases of myopathy occurred 
in patients treated with 80 mg daily and CPK elevations 
resolved following withdrawal of rosuvastatin.41
A retrospective matched cohort study compared the 
incidence rates of hospitalization associated with rhabdo-
myolysis, myopathy, renal or hepatic dysfunction, and of in-
hospital death, among over 48,000 initiators of rosuvastatin 
and other statins. This study found no difference between 
rosuvastatin and the other statins in the incidence of hospi-
talization because of renal or hepatic dysfunction, or death, 
while the absolute incidence rates of rhabdomyloysis and 
myopathy were reassuringly low among all statin initiators 
but remain too small for firm conclusions to be drawn on 
any difference between the statins. Particularly, incidence 
rate per 1000 person-years of rhabdomyolysis was 0.1 
among subjects taking rosuvastatin and 0.06 among those 
taking other statins, while incidence rate of myopathy was 
0.2 among rosuvastatin-treated subjects and 0 among other 
statin initiators.42
The safety and tolerability of rosuvastatin were evaluated 
using data from 16,876 patients who received rosuvastatin 5 to 
40 mg daily in a multinational phase II/III/IIIb/IV program. 
Adverse events irrespective of causality assessment occurred 
in 52.1% of patients receiving rosuvastatin and 51.8% of those 
receiving placebo. In all controlled clinical trials with com-
parator statins, rosuvastatin 5 to 40 mg was associated with an 
adverse event profile similar to profiles for atorvastatin 10 to 
80 mg, simvastatin 10 to 80 mg, and pravastatin 10 to 40 mg. 
Clinically significant elevations in ALT were uncommon in 
the rosuvastatin and comparator groups, and elevated CPK 
levels more than 10 times laboratory ULN occurred in 0.3% 
of patients receiving rosuvastatin or other statins. Myopathy 
possibly related to treatment was reported in 0.03% of patients 
taking rosuvastatin at doses of 5 to 40 mg. The frequency 
of dipstick-positive proteinuria at a rosuvastatin dose 5 to 
40 mg was comparable to that seen with other statins, and 
the occurrence of proteinuria was not predictive of acute or 
chronic renal disease. However, both short- and long-term 
rosuvastatin treatments were associated with small increases 
in estimated glomerular filtration rate.43
An observational cohort study was designed to monitor 
the postmarketing safety of rosuvastatin using prescription-
event monitoring. The cohort comprised 11,680 patients with 
a median period of treatment of 9.8 months, and rosuvastatin 
was found to be reasonably well tolerated. Myalgia was the 
most common reason for stopping rosuvastatin and the most 
frequently reported clinical event. A 2.5-fold increase in the 
rate of abnormal liver function tests was observed for patients 
started on rosuvastatin 40 mg daily compared with those 
started on 10 mg daily, while no case of rhabdomyolysis 
was reported in this cohort.44
Anti-inflammatory effects  
of rosuvastatin
Recent data have show multiple mechanisms for statins in 
reducing the risk of cardiovascular diseases. In particular, 
the HMG-CoA reductase inhibitors reduce the incidence of 
ischemic heart disease, improve endothelial function, reduce 
left ventricular hypertrophy and adverse remodeling, slow 
atherosclerotic process, and reduce serum levels of pro-
inflammatory cytokines.45
Recently, the in vitro effects of statins on peripheral 
blood mononuclear cells and fibroblast-like synoviocytes 
were analyzed in 25 patients with rheumatoid arthritis and 
in 20 healthy blood donors. In fibroblast-like cells stimu-
lated with atorvastatin a significant downregulation of 
proinflammatory cytokine (interleukin-6) and chemokine Drug, Healthcare and Patient Safety 2009:1 31
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(interleukin-8) expression was detected, showing a marked 
in vitro anti-inflammatory activity of atorvastatin in rheu-
matoid arthritis, including a systemic effect on a pathogenic 
CD4+ T cell population and a local effect on fibroblast-like 
synoviocytes.46 Moreover, simvastatin and atorvastatin inhibited 
the CRP-induced chemokine secretion, intercellular adhesion 
molecule (ICAM-1) upregulation, and migration in human 
adherent monocytes, through the inhibition of HMG-CoA 
reductase-extracellular signal-regulated kinase 1/2 pathway.47
The effect of rosuvastatin on plasma inflammation 
markers, endogenous nitric oxide synthase inhibitor levels, 
and reactive oxygen species generated by circulating leuko-
cytes was evaluated in normotensive and in spontaneously 
hypertensive rats. In the experimental conditions, rosuvastatin 
lessened pro-inflammatory cytokines, increased interleukin-4 
levels, and reduced reactive oxygen species production in 
circulating monocytes of spontaneously hypertensive rats.48
The effect of rosuvastatin on CRP expression in stimu-
lated human hepatocytes was also investigated. Experimental 
results showed a direct inhibitory effect of rosuvastatin on 
interleukin-6-induced expression of CRP in human hepatoma 
cells and primary human hepatocytes. Statins may reduce 
C-reactive protein levels by inhibiting its production in the 
liver rather than by exerting systemic anti-inflammatory 
effects.49
The anti-inflammatory properties of rosuvastatin and 
other HMG-CoA reductase inhibitors may have a great 
clinical utility in addition to their effects on atherogenic 
lipoproteins, and certainly require further laboratory and 
clinical in-depth examination.
Conclusions
The most appropriate algorithm for pharmacologic therapy 
in patients with hypocholesterolemia is summarized in 
Figure 2.
Rosuvastatin could be considered a second-generation 
HMG-CoA reductase inhibitor with unique pharmacokinetic 
and pharmacodynamic properties. Its chemical structure 
allows additional HMG-CoA reductase enzyme-binding 
interactions that cause tighter binding, and in vitro studies 
have shown a substantial active transport into hepatocytes, 
with the lowest IC50 for sterol synthesis in liver cells. As a 
consequence, rosuvastatin at dosages ranging from 10 to 
80 mg daily has demonstrated superior efficacy in lowering 
LDL cholesterol levels compared to milligram-equivalent 
dosages of atorvastatin, simvastatin, and pravastatin. More-
over, the lower lipophilicity of rosuvastatin is associated with 
poor penetration in extrahepatic tissues such as human umbil-
ical vein endothelial cells and fibroblasts, with a lower risk of 
muscle toxicity. Rosuvastatin metabolism is characterized by 
a low potential for cytochrome P450 involvement and a lower 
risk of drug–drug interactions with other drugs extensively 
metabolized by this hepatic pathway. This statin was usually 
well tolerated and the safety profile was comparable to that 
of other statins currently available, and has shown significant 
anti-inflammatory effects in experimental conditions. In this 
Figure 2 Algorithm for drug-therapy of hypercholesterolemia.
Abbreviation: LDL, low-density lipoprotein.
Initiate LDL-lowering
drug therapy
6 weeks
6 weeks
4−6 months
If LDL goal not achieved,
intensify LDL-lowering therapy
If LDL goal not achieved,
intensify LDL-lowering therapy
or refer to a lipid specialist
Monitor response and
adherence to therapy
(Start statin or bile acid
sequestrant or nicotinic
acid)
(Consider higher dose of statin
or add a bile acid sequestrant or
nicotinic acid)Drug, Healthcare and Patient Safety 2009:1 32
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context, rosuvastatin could be very helpful for the treatment 
of hypercholesterolemia.
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